Department of Gynaecology, The First People,s Hospital of Zunyi, The Third Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, China.
Contrast Media Mol Imaging. 2022 Jun 8;2022:7195888. doi: 10.1155/2022/7195888. eCollection 2022.
To discuss the evaluation value of CT in the efficacy of neoadjuvant chemotherapy in patients with ovarian cancer.
The clinical, pathological, and CT imaging information of 72 patients with ovarian cancer treated in our hospital from January 2018 to January 2022 were retrospectively analyzed. CT examination and pathological examination were compared to evaluate the efficacy of neoadjuvant chemotherapy.
Using the CRS grading system, 26 cases (36.11%) scored 1, 42 cases (58.33%) scored 2, and 4 cases (5.56%) scored 3. CRS grading system scores of 1, 2, 3, and 4-7 patients were compared, > 0.05. The CT manifestations of lymphadenectasis, degree of peritoneal thickening, ascites, and maximum length diameter of the mass were compared between the patients before and after chemotherapy, < 0.05. According to RECIST 1.1, there were 1 (1.39%) CR, 38 (52.78%) PR, 29 (40.28%) SD, and 4 (5.56%) PD. The comparison was done between RECIST 1.1 and CRS grading system, > 0.05.
CT could be used to evaluate the efficacy of neoadjuvant chemotherapy for ovarian cancer.
探讨 CT 在卵巢癌新辅助化疗疗效评估中的价值。
回顾性分析我院 2018 年 1 月至 2022 年 1 月收治的 72 例卵巢癌患者的临床、病理和 CT 影像学资料，将 CT 检查与病理检查进行对比，评价新辅助化疗的疗效。
采用 CRS 分级系统，26 例（36.11%）评分为 1 分，42 例（58.33%）评分为 2 分，4 例（5.56%）评分为 3 分。1、2、3、4-7 分患者的 CRS 分级系统评分比较，>0.05。化疗前后患者的淋巴结肿大、腹膜增厚程度、腹水、肿块最大径线的 CT 表现比较，<0.05。根据 RECIST 1.1 标准，1 例（1.39%）为完全缓解（CR），38 例（52.78%）为部分缓解（PR），29 例（40.28%）为疾病稳定（SD），4 例（5.56%）为疾病进展（PD）。RECIST 1.1 标准与 CRS 分级系统比较，>0.05。
CT 可用于评估卵巢癌新辅助化疗的疗效。
